News Line

The title Stallergenes soaring

July 16, 2010

The title of the pharmaceutical Stallergenes, specializing in the treatment of respiratory diseases related to allergies, a sign of the largest increases in the Paris Bourse. Around 14:15, the action is gaining 3.15% to 56.73 euros on a market up 0.25%.

Investors reacted positively to the publication Thursday of the group's turnover for the second quarter of 2010. Up 14%, it amounts to 47.3 million euros. In the first six months of the year, it reached 110.6 million euros, an increase of 13%.

Sales growth was helped by the good results of the drug Oralair in Germany, the first country to market.The drug will be launched in autumn in the Netherlands, Czech Republic, Slovakia and Austria.

The group, owned 46% by Wendel, raised its forecast for the year: it now expects an increase of at least 10% of its activity against 8% announced in April.

• The German economy, an island of prosperity in a continent devastated
• The pharmaceutical file has become
• After the solar Mersen diversified into health
• Wages: Businesses ungenerous in 2011
• Paris in decline despite SocGen